|  |
| --- |
| **Gender Disparities in Head and Neck Cancer Chemotherapy Clinical Trials Participation and Treatment.** Table 1. Proportion of women participating in NCCN cited head and neck cancer chemotherapy clinical trials and diagnosed with HNSCC in the U.S. by year of enrollment  |
|  | All Countries  | U.S. Only | Non-U.S. Countries | U.S. |
| Year  | Total Analyzed | WomenN (%) | Total Analyzed | WomenN (%) | Total Analyzed | WomenN (%) | Total Disease Burden  | WomenN (%) |
| Total 1985-2017 | 9,146 | 1,291(14.1% ) | 5388 | 915 (17.0%) | 3758 | 376 (10.0%) | 197,313 | 51,744 (26.2%) |
| 1985 | 50 | 4 (8.0%) | 50 | 4 (8.0%) | 0 | 0 (0%) | 2713 | 721 (26.6%) |
| 1986 | 115 | 14 (12.2%) | 115 | 14 (12.2%) | 0 | 0 (0%) | 2638 | 721 (27.3%) |
| 1987 | 115 | 14 (12.2%) | 115 | 14 (12.2%) | 0 | 0 (0%) | 2754 | 786 (28.5%) |
| 1988 | 166 | 22 (13.2%) | 166 | 22 (13.2%) | 0 | 0 (0%) | 2661 | 712 (26.8%) |
| 1989 | 166 | 22 (13.2%) | 166 | 22 (13.2%) | 0 | 0 (0%) | 2706 | 786 (29.0%) |
| 1990 | 51 | 8 (15.7%) | 51 | 8 (15.7%) | 0 | 0 (0%) | 2739 | 742 (27.1%) |
| 1991 | 51 | 8 (15.7 %) | 51 | 8 (15.7 %) | 0 | 0 (0%) | 2630 | 740 (28.1%) |
| 1992 | 131 | 25 (19.1%) | 91 | 17 (18.7%) | 40 | 8 (20.0%) | 3672 | 985 (26.8%) |
| 1993 | 102 | 19 (18.6%) | 102 | 19 (18.6%) | 0 | 0 (0%) | 3632 | 1035 (28.5%) |
| 1994 | 205 | 28 (13.6%) | 102 | 18 (17.6%) | 103 | 10 (9.7%) | 3641 | 1019 (28.0%) |
| 1995 | 274 | 37 (13.5%) | 171 | 28 (16.4%) | 103 | 9 (8.7%) | 3589 | 1011(28.2%) |
| 1996 | 274 | 37 (13.5%) | 171 | 28 (16.4%) | 103 | 9 (8.7%) | 3697 | 1083 (29.3%) |
| 1997 | 402 | 63 (15.7%) | 299 | 54 (18.1%) | 103 | 9 (8.7%) | 3659 | 1025 (28.0%) |
| 1998 | 442 | 61 (13.8%) | 299 | 54 (18.1%) | 143 | 7 (4.9%) | 3713 | 1074 (28.9%) |
| 1999 | 849 | 131 (15.4%) | 607 | 115 (18.9%) | 242 | 16 (6.6%) | 3605 | 1046 (29.0%) |
| 2000 | 924 | 132 (14.3%) | 496 | 94 (19.0%) | 428 | 38 (8.9%) | 7979 | 2099 (26.3%) |
| 2001 | 763 | 107 (14.2%) | 289 | 54 (18.7%) | 474 | 53 (11.2%) | 8203 | 2233 (27.2%) |
| 2002 | 586 | 87 (14.8%) | 206 | 37 (18.0%) | 380 | 50 (13.2%) | 8228 | 2129 (25.9%) |
| 2003 | 423 | 64 (15.1%) | 259 | 45 (17.4%) | 164 | 19 (11.6%) | 8097 | 2124 (26.2%) |
| 2004 | 559 | 71 (12.7%) | 188 | 37 (19.7%) | 371 | 34 (9.2%) | 8562 | 2230 (26.0%) |
| 2005 | 532 | 65 (12.2%) | 150 | 26 (17.3%) | 382 | 39 (10.2%) | 8227 | 2115 (25.7%) |
| 2006 | 314 | 43 (14.0%) | 151 | 26 (17.2%) | 163 | 17 (10.4%) | 8807 | 2313 (26.3%) |
| 2007 | 183 | 20 (10.9%) | 29 | 3 (10.3%) | 154 | 17 (11.0%) | 9048 | 2296 (25.4%) |
| 2008 | 78 | 7 (9.0%) | 29 | 4 (13.8%) | 49 | 3 (6.1%) | 9398 | 2427 (25.8%) |
| 2009 | 18 | 1 (5.6%) | 0 | 0 (0%) | 18 | 1 (5.6%) | 9779 | 2490 (25.5%) |
| 2010 | 18 | 1 (5.6%) | 0 | 0 (0%) | 18 | 1 (5.6%) | 9861 | 2520 (25.6%) |
| 2011 | 18 | 1 (5.6%) | 0 | 0 (0%) | 18 | 1 (5.6%) | 10159 | 2513 (24.7%) |
| 2012 | 242 | 36 (14.9%) | 242 | 36 (14.9%) | 0 | 0 (0%) | 10366 | 2590 (25.0%) |
| 2013 | 361 | 53 (14.6%) | 301 | 45 (14.9%) | 60 | 8 (13.3%) | 10593 | 2609 (24.6%) |
| 2014 | 373 | 59 (15.8%) | 312 | 53 (17.0%) | 61 | 6 (9.8%) | 10943 | 2734 (25.0%) |
| 2015 | 241 | 37 (15.4%) | 180 | 30 (16.7%) | 61 | 7 (11.4%) | 11014 | 2764 (25.1%) |
| 2016 | 60 | 7 (11.7%) | 0 | 0 (0%) | 60 | 7 (11.7%) | n/a | n/a |
| 2017 | 60 | 7 (11.7%) | 0 | 0 (0%) | 60 | 7 (11.7%) | n/a | n/a |
| Abbreviations: NCCN=national comprehensive cancer network; HNSCC=head and neck squamous cell carcinoma; U.S.=United States |

|  |
| --- |
| Table 2. Baseline Patient and Tumor Characteristic. Head and Neck Squamous Cell Carcinoma cohort identified in *Incidence- SEER 18 Registries Research Data (1985-2015).*  |
|  |  | **Sex N (%)** |  |
|  | **All** | **Male** | **Female** | **P Value** |
| **All Subsites**  | 197,313 (100%) | 145,569 (73.8%) | 51,744 (26.2%) | <0.001 |
| Larynx | 61,514 (31.2%) | 49,409 (80.3%) | 12,105 (19.7%) |  |
| Oral Cavity | 61,809 (31.3%) | 37,740 (61.1%) | 24,069 (38.9%) |  |
| Oropharynx | 55,473 (28.1%) | 44,604 (80.4%) | 10,869 (19.6%) |  |
| Hypopharynx | 12,767 (6.5%) | 10,099 (79.1%) | 2,668 (20.9%) |  |
| Sinonasal Tract | 5,750 (2.9%) | 3,717 (64.6%) | 2,033 (35.4%) |  |
| **Age** |  |  |  | <0.001 |
| 18-54 | 45,987 (23.3%) | 35,134 (76.4%) | 10,853 (23.6%) |  |
| 55-64 | 59,694 (30.3%) | 46,616 (78.1%) | 13,078 (21.9%) |  |
| 65-74 | 52,636 (26.7%) | 38,984 (74.1%) | 13,652 (25.9%) |  |
| >/=75 | 38,996 (19.8%) | 24,835 (63.7%) | 14,161 (36.3%) |  |
| **Race** |  |  |  | <0.001 |
| White | 164,235 (83.2%) | 120,756 (73.5%) | 43,479 (26.5%) |  |
| Black/African American | 22,832 (11.6%) | 17,507 (76.7%) | 5,325 (23.3%) |  |
| Asian/Pacific Islander | 8,251 (4.2%) | 5,825 (70.6%) | 2,426 (29.4%) |  |
| American Indian | 992 (0.5%) | 744 (75.0%) | 248 (25.0%) |  |
| Other/Unknown | 1,003 (0.5%) | 737 (73.5%) | 266 (26.5%) |  |
| **AJCC T Stage** |  |  |  | <0.001 |
|  T1 | 35,105 (17.8%) | 25,485 (72.6%) | 9,620 (27.4%) |  |
|  T2 | 30,525 (15.5%) | 23,053 (75.5%) | 7,472 (24.5%) |  |
|  T3 | 14,621 (7.4%) | 11,328 (77.5%) | 3,293 (22.5%) |  |
|  T4 | 19,899 (10.1%) | 15,236 (76.6%) | 4,663 (23.4%) |  |
|  T0,X,N/A  | 97,163 (49.2%) | 70,467 (72.5%) | 26,696 (27.5%) |  |
| **AJCC N Stage** |  |  |  | <0.001 |
|  N0 | 57,109 (28.9%) | 40,540 (71.0%) | 16,569 (29.0%) |  |
|  N1 | 17,034 (8.6%) | 12,780 (75.0%) | 4,254 (25.0%) |  |
|  N2 | 33,335 (16.6%) | 26,819 (80.5%) | 6,516 (19.5%) |  |
|  N3 | 3,017 (1.5%) | 2,600 (86.2%) | 417 (13.8%) |  |
|  NX,N/A  | 86,818 (44.0%) | 62,830 (72.4%) | 23,988 (27.6%) |  |
| **AJCC M Stage** |  |  |  | <0.001 |
|  M0 | 106,770 (54.1%) | 79,718 (74.7%) | 27,052 (25.3%) |  |
|  M1 | 3,895 (2.0%) | 3,087 (79.3%) | 808 (20.7%) |  |
|  MX,N/A | 86,648 (43.9%) | 62,764 (72.4%) | 23,884 (27.6%) |  |
| **AJCC Stage 6th Edition** |  |  |  | <0.001 |
|  I | 25,005 (12.7%) | 17,739 (70.9%) | 7,266 (29.1%) |  |
|  II | 13,477 (6.8%) | 9,590 (71.2%) | 3,887 (28.8%) |  |
|  III | 16,542 (8.4%) | 12,327 (74.5%) | 4,215 (25.5%) |  |
|  IV | 48,109 (24.4%) | 38,101 (79.2%) | 10,008 (20.8%) |  |
|  N/A | 94,180 (47.7%) | 67,812 (72.0%) | 51,744 (26.2%) |  |